Please enable JavaScript in your web browser settings, under the site permissions section to unlock full site functionality. Click here for help.

Article Image - OPKO Health Acquires EirGen Pharma

Posted 28th May 2015

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

Scroll to keep reading

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

View Biography

Paul Heffernan, Legal Adviser OPKO Health

OPKO Health, Inc. is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than 40 others around the world.

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art high containment research and development, and manufacturing facility, is approved by the FDA, EMEA (European Health Authorities) and the PMDA (Japanese Health Authorities). High potency drugs such as those used for cancer chemotherapy are typically unsuitable for manufacture in normal multi-product facilities due to cross contamination risks.

To date, EirGen and its commercial partners have filed 10 product applications with the FDA and 5 each in Europe and Japan. EirGen has a strong research and development portfolio of over 20 niche, high barrier to entry drugs and, with access to additional capital that OPKO will provide, together with the benefits of Irish government programs to encourage research and development in Ireland, EirGen will rapidly expand its drug portfolio.

“EirGen Pharma is one of the leading developers and suppliers of high potency niche pharmaceutical products in the world,” said Phillip Frost, M.D. OPKO’s Chairman and CEO. “As FineTech, OPKO’s Israeli active pharmaceutical ingredient manufacturing subsidiary, is also focused on high potency drugs, an immediate business synergy is expected. EirGen also offers the significant benefit of potentially being able to manufacture OPKO’s current and future products in our own facilities, which we expect will result in even higher gross margins. The superb management, research and development, manufacturing and product distribution teams, along with state of the art facilities, together, will create an important, tax efficient base of operations for OPKO,” said Dr. Frost.

Categories: M&A, Strategy

You Might Also Like

How Workflow helps your Organization Connect Tools and Teams to Drive Productivity

06/05/2022How Workflow helps your Organization Connect Tools and Teams to Drive Productivity

A competitive workflow contains effective features and work tools that help organizations accomplish their business process. Workflow tools are simple information systems that allow businesses to build and optimize their processes. The tools help users build a

5 Borrowing Options for Low or No Credit Score

30/05/20235 Borrowing Options for Low or No Credit Score

In today’s inflationary periods, being in dire need of additional funds are inevitable. However, accessing them is no picnic since most financial companies will require borrowers to have good credit.

Restructuring options for financially-distressed employers

17/03/2021Restructuring options for financially-distressed employers

Whilst support has been made available by the Government to assist employers, the pandemic has still seen huge numbers of job losses. The pain has been felt in all sectors. So, what restructuring options are available for directors to consider in the hope of r

Turbocharge Your Marketing with AI: A Modern Guide to Smarter Campaigns

25/06/2025Turbocharge Your Marketing with AI: A Modern Guide to Smarter Campaigns

If you want to break away from outdated marketing methods and actually connect with your audience, artificial intelligence isn’t a luxury—it’s a requirement.

451 Research Identifies Nearly 300 M&A and IPO Candidates in its Annual 2016 Tech M&A Outlook

25/02/2016451 Research Identifies Nearly 300 M&A and IPO Candidates in its Annual 2016 Tech M&A Outlook

According to 451 Research’s recently published Tech M&A Outlook 2016, acquirers will spend hundreds of billions of dollars on tech acquisitions in the coming year to adapt to a rapidly changing marketplace with notable hotspots in information security, IoT a

Should You Have a Mortgage During Retirement

30/10/2023Should You Have a Mortgage During Retirement

Retirement is something most of us look forward to with great excitement and expectation, offering us an opportunity to enjoy the fruits of our labor while taking up hobbies we truly care about. One key decision often raised when entering retirement is whether

CFH Docmail Acquisition of BSS Scotmail

04/08/2015CFH Docmail Acquisition of BSS Scotmail

CFH Docmail Acquisition of BSS Scotmail

Shaping the Future in the Digital Age

06/02/2024Shaping the Future in the Digital Age

For the best part of the last two decades, Liliana Bakayoko has been a vital cog in the works when it comes to assisting national and international clients with matters of law.

Scams to be aware of as a professional

06/05/2021Scams to be aware of as a professional

There are numerous opportunities to grow in the business world. You might start a company or look for the best places to invest money, but opportunities aren’t always what they seem to be. These are the most common scams to be aware of as a professional, so

View More Articles

Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

MORE BRANDS